TEM · Tempus AI Inc
Price
Snapshot
50 fields · last close| Market Cap | $14.05B |
| P/E | — |
| Float | 110.1M |
| Beta | 2.33 |
| Volatility | 58.4% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Very High |
| Clavix score | 37 |
| Price | 78.52 |
| Change | +0.87% |
| Prev Close | 77.84 |
| Open | 81.40 |
| Day Low | 75.99 |
| Day High | 81.83 |
| Avg Vol | 7 |
| Avg $ Vol | $563.2M |
| 52W High | 104.32 |
| 52W Low | 40.77 |
| 52W Pos | 59.4% |
| From High | −24.73% |
| From Low | +92.59% |
| Max DD 1Y | −59.76% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +18.08% |
| SMA 50 | +37.60% |
| SMA 200 | +39.83% |
| RSI (14) | 67.8 |
| Vol 30D | 108.4% |
| Vol 90D | 86.0% |
| 1Y Range | 41–104 |
| Daily bars | 516 |
| Perf Week | +31.91% |
| Perf Month | +27.09% |
| Perf Quarter | +53.11% |
| Perf Half Y | +59.70% |
| Perf Year | −9.96% |
| Perf YTD | +25.91% |
| Prev Day | +0.87% |
| Clavix | D- |
| Debt / Eq | 2.52 |
| Curr Ratio | 3.13 |
| Int Cover | -2.4× |
| FCF Margin | — |
| Rev Growth | +21.6% |
| Profit | Unprofitable |
| Leverage | High |
| Sector rank | 19 / 19 |
Clavix risk grade
regraded every trading dayTEM grades D-, 37 of 100. Steadiest on News Sentiment (61), most exposed on Price Stability (21, weak). 0 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 19 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| TEM | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.33 | 1.18 |
| Volatilityannualized | 58.4% | 29.6% |
| Max drawdown, past yearworst peak-to-trough fall | −59.8% | — |
| Typical daily movemedian absolute daily change | 2.72% | — |
| Days beyond ±3%of the last 252 sessions | 11847% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| TEM | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.33 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Moderate47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| TEM | |
|---|---|
| 1 week | +31.9% |
| 1 month | +27.1% |
| Year to date | +25.9% |
| 1 year | −10.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| TEM | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 20 Aug |
| Average score0 most bearish, 100 most bullish | 65 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 5 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| TEM | |
|---|---|
| Revenue growthyear over year | +21.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openTempus AI (TEM) extended its multi-year data license agreement with Recursion Pharmaceuticals through November 2029, and the two companies also signed a new deal in which Tempus will license Recursion's RNA Foundation Model. Both companies say they share a goal of using foundation models to advance precision medicine. The article text is cut off and does not provide further financial details.
Tempus AI announced a multi-year initiative to build a research platform of 100,000 whole human genomes linked to clinical, imaging, pathology and outcome data, with plans to scale toward one million genomes and offer broad access through its Tempus Lens environment by mid-2027. The stock is up 31.9% since the announcement. The article body is truncated and does not specify a confirmed catalyst for the price move beyond the announcement.
Tempus AI announced a new whole-genome sequencing project that links complete DNA readings with patient medical records and imaging data, with the goal of building a dataset of one million whole genomes for use in drug development and personalized care.
Tempus AI's CEO Ryan Fukushima sold 700 shares of company stock on September 16th for $70.00 each, totaling $49,000. After the sale, he still owns 15,874 shares worth roughly $1.1 million, meaning the transaction reduced his stake by about 4.22%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which is a schedule insiders set up in advance to sell shares automatically without needing fresh approval each time.
Tempus AI's Chief Accounting Officer Ryan Bartolucci sold 7,062 shares at $75.00 each on September 17th, totaling $529,650. After the sale he still held 60,804 shares worth about $4.56 million, a 10.41% reduction in his personal stake.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CRL | Charles River Laboratories International Inc | B- | $13.27B | — | 1.41 | Compare |
| RVTY | Revvity Inc | B | $16.01B | 67.38 | 1.09 | Compare |
| MEDP | Medpace Holdings Inc | B | $17.09B | 34.77 | 1.13 | Compare |
| TECH | Bio-Techne Corp | B | $11.35B | 62.40 | 1.30 | Compare |
| AVTR | Avantor Inc | B- | $10.50B | — | 0.97 | Compare |
| RGEN | Repligen Corp | B- | $9.98B | 240.33 | 1.14 | Compare |
| TXG | 10X Genomics Inc | C- | $9.98B | — | 2.04 | Compare |
| BRKR | Bruker Corp | C | $9.35B | — | 1.25 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.